SCHEMBL5757330

SCHEMBL5757330

COC(=O)[C@H](C)Oc1ccc(Br)cc1OC(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 4/20 0.41
LMNA P02545 1/20 0.41
ATM Q13315 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SLC6A4 P31645 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
F9 P00740 1/20 0.39
PLAU P00749 1/20 0.39
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
HSD11B1 P28845 1/20 0.38
KCNK3 O14649 1/20 0.38
KCNK9 Q9NPC2 1/20 0.38
EPHX2 P34913 1/20 0.37
HRH4 Q9H3N8 1/20 0.37
KDR P35968 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5758294 0.86 KMT2A (0.45) ALPLLMNAATMSMN1; SMN2SLC6A4
SCHEMBL22805224 0.81 PTGDR2 (0.41) ALPLLMNAATMSMN1; SMN2F9
SCHEMBL22805225 0.81 PTGDR2 (0.41) ALPLLMNAATMSMN1; SMN2F9
SCHEMBL29530222 0.80 ALDH1A1 (0.42) LMNAATMSMN1; SMN2F9PLAU
SCHEMBL29091950 0.80 ALDH1A1 (0.42) LMNAATMSMN1; SMN2F9PLAU
SCHEMBL27235800 0.80 ALDH1A1 (0.42) LMNAATMSMN1; SMN2F9PLAU
SCHEMBL3007597 0.79 SLC6A4 (0.44) ALPLLMNASMN1; SMN2SLC6A4MAOA
SCHEMBL21095341 0.79 TSHR (0.48) LMNAATMSMN1; SMN2HSD11B1ALDH1A1
SCHEMBL22805702 0.78 LMNA (0.44) LMNAATMSMN1; SMN2F9PLAU
SCHEMBL22805703 0.78 LMNA (0.44) LMNAATMSMN1; SMN2F9PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663234-A1 PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS Pfizer Limited (GB) 2006-06-07 EP disclosed
US-20050043300-A1 Piperazine derivatives PFIZER INC. 2005-02-24 US disclosed
WO-2005016344-A1 PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS PFIZER LIMITED (GB) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043300-A1 Piperazine derivatives CD4, CCR5, RRP15 ALPL 4640/4885LMNA 3961/4885ATM 4814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.